Vaccine

Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate

Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant…

3 hours ago

Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting

Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS…

12 hours ago

Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting

Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS…

12 hours ago

Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting

Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS…

12 hours ago

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19

mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized productmCOMBRIAX will…

12 hours ago

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19

mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized productmCOMBRIAX will…

12 hours ago

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19

mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized productmCOMBRIAX will…

12 hours ago

Deadly Measles Cases Accentuate the Need for a Treatment – NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),…

15 hours ago

Deadly Measles Cases Accentuate the Need for a Treatment – NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),…

15 hours ago

Moderna to Present at Upcoming Conferences in May 2026

CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following…

15 hours ago